Drug pricing decisions have come under intense scrutiny. Over the past several weeks, an FTC investigation, federal and state legislative initiatives, and agency compliance investigations have commenced. Substantiating pricing decisions by value-based health evidence and demonstrating strong pricing compliance records are important to navigating such investigations and initiatives.
2024 Advertising CLE Showcase: Is it Time to Toss the “Junk Fees?” An Update on Regulatory and Class Action Risks Associated with Added Fees
2024 Advertising CLE Showcase: Influencers, Testimonials, Consumer Reviews and Sponsored Content in Advertising